CHRS
Coherus Oncology, Inc.
$1.61
Stable Earnings Power
40%
P/Adj-EPS × Normalized Multiple
Strong
·
Conviction
Undervalued
Trading 88.8% below fair value
You pay
$1.61
Bear
$12.36
Fair
$14.42
Bull
$16.48
Bear
$12.36
+667.7%
$1.23 × 12x P/E
Fair
$14.42
+795.7%
$1.23 × 14x P/E
Bull
$16.48
+923.6%
$1.23 × 16x P/E
Key Value Driver
Normalized P/E multiple (14x base case)
Implied Market Multiple
1.3x
Summary
Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $6.02 from 16 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $14.42 per share.
Warnings
Wall Street's average price target is $6.02 (from 16 analysts). Our estimate is 186% above the consensus -- consider that gap carefully.
Key Risks
- Growth DCF inappropriate — terminal value assumptions dominate
- EV/EBITDA misleading for regulated businesses where capex is mandated
- Regulatory risk is a fat tail not visible in normal multiples